[A24-67] Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V
Last updated 22.11.2024
Project no.:
A24-67
Commission:
Commission awarded on 30.05.2024 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Kidneys and urinary system
Adult patients with symptomatic anaemia associated with chronic kidney disease (CKD) who are on chronic maintenance dialysis
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A24-67_en
| Project no. | Title | Status |
|---|---|---|
| A24-106 | Vadadustat (symptomatic anaemia associated with dialysis-dependent chronic kidney disease) – Addendum to Project A24-67 | Commission completed |
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.